DOAC

EP 105: The Year 2023 in Review with Dr Sukh Nijjer

Ankur Kalra, Sukhjinder Nijjer,

Listen time: 1h 3m 40s
Parallax: The Year 2023 in Review with Dr Sukh Nijjer

Ankur Kalra, Sukhjinder Nijjer,

Watch time: 1h 5m 20s
CardioNerds @AHA23: ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin

Naima Maqsood, Jeff Healey,

Watch time: 11m 15s
ESC 22: 3 Trials That Will Change Your Practice With Dr Afzal Sohaib

Afzal Sohaib,

Watch time: 3m 29s
ESC 22: APOLLO: Apixaban for Prevention of Thromboembolic Outcomes in COVID

Renato D Lopes,

Watch time: 3m 57s
ESC 22: ACT: Anti-Coronavirus Therapies to Prevent Progression of COVID-19

Sanjit Jolly,

Watch time: 4m 59s
ESC 22 Late-breaker Discussion: The INVICTUS Trial

Harriette Van Spall, Ganesan Karthikeyan,

Watch time: 17m 13s
View from the Thoraxcenter: ESC 22 Late-breaking Science Preview

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 24m 27s

Payam Pournazari , Su Min Chang , Stephen H Little , et al

ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR

Duk-Woo Park,

Watch time: 7m 44s
ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI

George D Dangas,

Watch time: 6m 33s
HRS 21: Results from the STROKE-VT Trial

Dhanunjaya Lakkireddy,

Watch time: 7m 8s

Alex Spyropoulos, Gary E Raskob,

Watch time: 1h 2m 6s

Payam Pournazari , Su Min Chang , Stephen H Little , et al

View from the Thoraxcenter: ESC 22 Late-breaking Science Preview

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 24m 27s
ESC 22 Late-breaker Discussion: The INVICTUS Trial

Harriette Van Spall, Ganesan Karthikeyan,

Watch time: 17m 13s

Philip J Devereaux, John Eikelboom,

Watch time: 17m 25s
ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI

George D Dangas,

Watch time: 6m 33s
Parallax: The Year 2023 in Review with Dr Sukh Nijjer

Ankur Kalra, Sukhjinder Nijjer,

Watch time: 1h 5m 20s
ESC 22: 3 Trials That Will Change Your Practice With Dr Afzal Sohaib

Afzal Sohaib,

Watch time: 3m 29s
HRS 21: Results from the STROKE-VT Trial

Dhanunjaya Lakkireddy,

Watch time: 7m 8s
ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR

Duk-Woo Park,

Watch time: 7m 44s
RC Live Stream: The MANAGE Late Breaking Trial - ACC 2018

Philip J Devereaux, John Eikelboom,

Watch time: 17m 25s
Dual Antithrombotic Therapy With Dabigatran

Christopher P Cannon,

Watch time: 5m 44s

Media

Parallax: The Year 2023 in Review with Dr Sukh Nijjer

Ankur Kalra, Sukhjinder Nijjer,

Watch time: 1h 5m 20s
HRS 2020: Incidence of Silent Brain Infarcts in Anticoagulated Patients with AF

David Conen,

Watch time: 7m 38s
CardioNerds @AHA23: ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin

Naima Maqsood, Jeff Healey,

Watch time: 11m 15s

Alex Spyropoulos, Gary E Raskob,

Watch time: 1h 2m 6s

Philip J Devereaux, John Eikelboom,

Watch time: 17m 25s
ESC 22: APOLLO: Apixaban for Prevention of Thromboembolic Outcomes in COVID

Renato D Lopes,

Watch time: 3m 57s
ESC 22: ACT: Anti-Coronavirus Therapies to Prevent Progression of COVID-19

Sanjit Jolly,

Watch time: 4m 59s
Dual Antithrombotic Therapy With Dabigatran

Christopher P Cannon,

Watch time: 5m 44s
RC Live Stream: The MANAGE Late Breaking Trial - ACC 2018

Philip J Devereaux, John Eikelboom,

Watch time: 17m 25s
AHA 2019: Clinical Data Update on TWILIGHT and TWILIGHT-ACS

Marc P Bonaca, Roxana Mehran,

Watch time: 5m 5s
AHA 2019: Updates from GALILEO-4D

Ole De Backer,

Watch time: 4m 8s
ESC 2020: Edoxaban for Elderly AF Patients — Dr Ken Okumura

Ken Okumura,

Watch time: 8m 16s

Articles

Prosthetic Aortic Valve Thrombosis

Payam Pournazari

,

Su Min Chang

,

Stephen H Little

,

Sachin Goel

,

Nadeen N Faza

,

Published:

08 July 2022

Citation:

US Cardiology Review 2022;16:e17.

DOI:

https://doi.org/10.15420/usc.2021.19
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 3098
  • Downloads: Downloads 166
  • Citations: 1